1. Home
  2. OMER vs JANX Comparison

OMER vs JANX Comparison

Compare OMER & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$13.29

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

N/A

Current Price

$10.13

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OMER
JANX
Founded
1994
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
OMER
JANX
Price
$13.29
$10.13
Analyst Decision
Buy
Buy
Analyst Count
3
18
Target Price
$27.50
★ $33.14
AVG Volume (30 Days)
★ 1.2M
946.4K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 98.15
N/A
EPS
★ 0.13
N/A
Revenue
★ $29,868,000.00
$10,000,000.00
Revenue This Year
N/A
$174.21
Revenue Next Year
$66.13
N/A
P/E Ratio
$107.77
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.70
$10.16
52 Week High
$21.24
$35.34

Technical Indicators

Market Signals
Indicator
OMER
JANX
Relative Strength Index (RSI) 30.78 25.34
Support Level $9.45 N/A
Resistance Level $19.68 $14.47
Average True Range (ATR) 0.92 1.16
MACD -0.45 -0.48
Stochastic Oscillator 8.90 0.33

Price Performance

Historical Comparison
OMER
JANX

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: